Articles tagged with Cancer Immunology
Researchers found that certain antibodies can reduce antitumor immune cells, highlighting the need to consider ADCC activity when designing or selecting ICI therapeutics. This study could help improve cancer treatment by engineering antibodies that avoid damaging essential immune cells.
City of Hope research demonstrates a new drug combination that slows advanced prostate cancer growth without improving overall survival. A novel AI conversation tool helps scientists uncover gene-disease connections without programming expertise.
A new study published in JAMA Network Open found no statistical relationship between pathologic complete response (pCR) and overall survival in rectal cancer patients. This challenges the FDA's use of pCR as a surrogate endpoint for drug approval, which may lead to treatments being fast-tracked without evidence of improved long-term su...
Researchers Sontheimer and Monje have made groundbreaking discoveries in brain tumor growth, revealing how nerve cells promote the development of aggressive gliomas. Their work has laid the foundation for new treatments and clinical trials, offering hope for innovative therapies.
Researchers at MD Anderson identified specific co-mutations in KRAS-mutant non-small cell lung cancer (NSCLC) that improve treatment response to ATR inhibitors. Additionally, chemotherapy was found to drive changes to the genome and clonal architecture of blood stem cells, increasing the risk of secondary malignancies.
The study reveals three new subsets of follicular T cells that increase in follicular lymphoma, each with distinct gene expression and spatial distribution patterns. These T-cell subsets serve as a strong predictor of patient prognosis, enhancing treatment approaches for the disease.
A genetically engineered herpes simplex virus, RP1, shows promise in treating advanced melanoma when combined with immunotherapy. In a phase 1-2 clinical trial, one-third of patients experienced significant tumor shrinkage or disappearance, offering hope to those with untreatable cancer.
Researchers identify new group of immune cells driving autoimmune attack on insulin-producing cells in pancreas during cancer immunotherapy. JAK inhibitors, already FDA-approved for psoriasis and arthritis, show potential to prevent and even reverse type 1 diabetes in preclinical models.
Researchers discovered that breast cancer responds to CDK4/6 inhibitors by forming an immunosuppressive microenvironment, which can be mitigated with radiation therapy or immune-modulating drugs. The study also found a potential biomarker to predict treatment response in patients.
Scientists have discovered that CD4 T cells can target tumour cells with high efficiency, expanding the pool of patients who could benefit from this therapy. A clinical trial is currently preparing to test this approach in adults and children with various types of cancer.
Researchers at MD Anderson have made significant breakthroughs in cancer treatment, including improved outcomes for elderly patients with IDH-mutant AML who are not eligible for intensive chemotherapy. Additionally, new targeted therapies have been approved as frontline treatments, while pre-surgical radiation therapy may offer an alte...
A comprehensive review highlights the impact of anti-cancer treatments on bone health, increasing the risk of fractures and bone fragility. The International Osteoporosis Foundation advocates for a multidisciplinary approach to early screening and proactive bone-protective strategies.
A proof-of-concept study shows that chimeric antigen receptors (CARs) can distinguish between tau tangles and various forms of toxic amyloid plaques, two key contributors to Alzheimer's disease pathology. The technology has the potential to deliver therapeutic drugs directly to affected areas of the brain with reduced side effects.
A pilot study found that exercising during chemotherapy can increase the number of immune cells fighting cancer, including CD8+ T cells and natural killer cells. The exercise programme improved patients' aerobic fitness, leading to stronger immune responses inside tumours.
Researchers at Ben-Gurion University of the Negev have made a breakthrough in harnessing patient's own T-cells to fight off cancer by creating artificial surfaces mimicking natural immune cells. These surfaces, engineered with nanostructures, strengthen and prolong activation of T-cells, leading to more effective immunotherapy.
The study identified key proteins and signaling pathways involved in CAR-T cell therapy's efficacy, including cytokines, kinases, receptors, proteases, and chemical messengers. The findings pave the way for new treatment advances and potential biomarkers.
Combining immunotherapy drug dostarlimab with standard chemotherapy improved survival and reduced symptoms in patients with advanced endometrial cancer. Patients lived up to 5.5 months longer with fewer side effects, outweighing risks.
Rapid advances in cancer treatment have improved long-term survival rates, but current resources and models of care in Canada do not meet the changing needs of people with cancer. The authors propose solutions such as reducing unnecessary surveillance and establishing interdisciplinary specialty clinics.
Researchers at Case Western Reserve University have developed a new device called CAPGLO that uses magnets to isolate disease-fighting T cells, making CAR T cell therapy potentially less expensive and more accessible. The technology aims to reduce the cost of immunotherapy from thousands to just hundreds of dollars.
Scientists have engineered a herpes virus to activate pathways in T cells, enhancing their ability to fight cancer. The approach uses proteins from the herpes virus to recruit enzymes that sustain T cell function in tumors.
Researchers identify five distinct immunotypes in tongue squamous cell carcinoma, shedding light on why current immunotherapies fail. The study's findings highlight the need for immune-based assessments to guide treatment decisions and suggest a new approach to personalized medicine.
The review highlights three key regulatory layers of T-cell plasticity: cellular signals, metabolic reprogramming, and physical and biological factors. Innovative therapeutic strategies, such as immune checkpoint therapy and adoptive cell therapy, aim to restore T-cell function and enhance antitumor immunity.
Researchers from City of Hope will present novel cancer treatment approaches and combinations, including innovative combination therapies for breast, genitourinary, and gastrointestinal cancers. Additionally, they'll discuss the safety of readministering trastuzumab-deruxtecan to metastatic breast cancer patients with low-grade lung co...
Researchers at MD Anderson Cancer Center have made significant discoveries in three key areas of cancer care. In a study on sickle cell disease, the team found that the disorder can suppress immunity by altering DNA structure in CD8+ T cells, leading to potential strategies for improving immunotherapy responses. Meanwhile, a biomarker-...
Researchers found that aging impairs CAR-T cell function and antitumor activity due to lower NAD levels. Rejuvenating aged cells with NAD-boosting compounds improves their effectiveness.
Researchers at The University of Osaka found that localized oxygen deficiency in colon tumors can promote tumor growth by transforming normal fibroblasts into inflammatory fibroblasts. These altered cells release factors that help tumors grow, offering a potential new target for cancer therapy.
A study found that blood cancer survivors are more likely to face financial hardship and take fewer medications due to high-cost immunotherapy treatments. Financial strain affects both Medicare-insured and uninsured patients, highlighting the need for better financial support and policy strategies.
The University of Texas at Arlington's nursing and physics team has developed a system to study alpha radiation, improving the effectiveness of radiation therapy. The team's research was recognized with the Best in Physics award at the American Association of Physicists in Medicine's annual meeting.
Researchers found that phospholipids in ascites fluid disrupt immune cell function, particularly NK cells, leading to impaired anti-tumor activity. Blocking these lipids can restore NK cell activity, providing a promising therapeutic target.
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.
This study compares laser-guided technology to conventional manual percutaneous lung biopsy, finding that laser-guided technology can reduce operational time and needle adjustments. However, it did not reduce complication rates or improve pathological diagnosis accuracy compared to traditional methods.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
A team of researchers has identified a novel oncometabolite that accumulates in tumors and impairs immune cells' ability to fight cancer. The study highlights how the metabolic environment of tumors influences T cell function, opening new possibilities for improving cancer immunotherapy by targeting tumor metabolism.
Berger has made significant contributions to cancer epigenetics and tumor biology. Her work has elucidated key mechanisms of p53 regulation and immune cell epigenetics, advancing our understanding of cancer biology.
Researchers at Cold Spring Harbor Laboratory have identified a connection between the brain and immune system responsible for cachexia-related apathy. By targeting specific neurons and immune system proteins, they hope to improve cancer patients' quality of life and tolerance for treatments.
A recent study by researchers at TUM has discovered that the body produces special T cells predisposed to exhaustion even in early infection phases of moderate diseases. This finding expands our understanding of immune response mechanisms and could help control the immune system in cancer patients or weaken excessive defenses.
The project aims to enhance CTC detection sensitivity and specificity for clinical needs in cancer early screening, diagnosis and treatment. The team will develop an integrated system covering CTC counting, classification and downstream detection of CTC proteins and genes.
Researchers have discovered double negative memory B cells, a novel subset of immune cells that are more dysfunctional when in close contact with tumors. These cells may be a useful diagnostic marker and a potential target for developing new immunotherapies.
Researchers discover mitochondrial transfer between cancer cells and immune cells as a key immune evasion strategy. Cancer cells can reshape the tumor microenvironment to weaken tumor-infiltrating lymphocytes, and mitochondria play a significant role in this process.
Researchers at the University of Melbourne have identified a rare type of immune cell, called stem-like T cells, that holds the key to maintaining powerful, long-term immune responses. ID3+ T cells have the remarkable ability to resist burnout and maintain a powerful immune response over time.
Researchers have discovered a key strategy through which persister cells evade the immune response and resist cancer treatments. Inhibiting an epigenetic mechanism could unlock inflammatory genes and compromise persister cell viability.
Scientists at Salk Institute discovered that removing bile acid-creating protein BAAT and adding bile acid UDCA controls tumor growth in mice with liver cancer. UDCA supplements may be a quick solution to improving liver cancer patient outcomes.
Scientists at Goethe University Frankfurt have discovered a new way to tailor natural killer cells to target leukemia cells, improving their efficacy. The researchers used CRISPR/Cas9 gene editing to disable an immune checkpoint, allowing the modified cells to attack cancer cells more effectively.
Researchers at Salk Institute establish a novel framework for the relationship between nutrition and cell identity. They found that a nutritional switch from acetate to citrate plays a key role in determining T cell fates, shifting them from active effector cells to exhausted cells.
Researchers at NYU Langone Health discovered two ways cancer cells evade chemotherapy's effects: by slowing down pyrimidine synthesis and activating anti-apoptotic proteins. This better understanding could lead to more effective combination therapies and diagnostic tests, ultimately improving patient outcomes.
Researchers at Michigan Medicine found that SLC13A3 transporter impairs tumor immunity by endowing ferroptosis resistance. This discovery suggests a potential target for improving immunotherapy responses in cancer patients.
A new mechanism has been found by which tumor cells escape the immune system, involving a protein called IRGQ. Studies have shown that suppressing IRGQ can trigger a stronger immune response against cancer cells, leading to improved survival rates in liver cancer patients.
Researchers at Penn State College of Medicine have re-engineered natural killer immune cells with blue light-activated protein function, allowing them to infiltrate and kill solid tumor spheroids. The technology has shown promising results in killing breast cancer and melanoma cells within seven days.
Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells that can be switched on and off with existing drugs, improving safety and efficacy in solid tumors. The design and preclinical evaluation of the CAR-T cells addresses the challenges of traditional therapy.
The developed pipeline, NeoDisc, integrates molecular and genetic analyses of tumors and utilizes artificial intelligence algorithms to identify personalized neoantigens for vaccine design. Researchers also show that NeoDisc provides a more accurate selection of effective cancer antigens than current computational tools.
A new method to construct protein complex-based therapeutics has been discovered using a polymer cloak, which stabilizes the delivery of protein complexes and enables tumor-targeted immunomodulation. The study presents an IL-15 nanosuperagonist with enhanced efficacy and specificity, promising a safer therapy for cancer treatment.
A phase 1b/2 clinical trial found a combination of immunotherapy and FGFR inhibitor to be safe and tolerable in patients with locally advanced or metastatic bladder cancer. The treatment showed increased response rates, including 54% for patients with high FGFR mRNA expression.
A recent study by Dr. Esteban Ballestar's group identifies an immune cell population that is more effective in responding against cancer cells under hypoxia. Macrophages undergo changes that enhance their ability to trigger an immune response, leading to better patient outcomes in bladder and ovarian cancers.
A new study published in Frontiers in Immunology reveals that certain food proteins like milk and meat can help keep gut tumors from growing by triggering the intestinal immune system. This discovery has potential clinical implications for patients with gastrointestinal conditions.
A study by IRB Barcelona researchers has identified five independent factors that determine patients' response and survival after receiving checkpoint inhibitors, a type of immunotherapy. These findings provide a framework for current and future biomarkers of immunotherapy response and could lead to more accurate patient classification.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Researchers have identified a shared molecular mechanism between pregnancy and cancer that suppresses the immune system. Progesterone was found to play a key role in this process, with blocking its signaling slowing down cancer growth in mice and activating the immune response.
Researchers develop optogenetic system to precisely target cancer cells using light, inducing inflammatory cell death and triggering immune response. The approach aims to modulate the immune suppressive environment around cancer cells, helping T cells recognize and attack the disease.
Researchers from Aarhus University have discovered that combining a cancer-fighting viral agent with the drug 4-Octyl-Itaconate (4-OI) enhances its effectiveness in treating resistant cancers. This groundbreaking finding may lead to new treatment options for previously incurable diseases.
A new immunotherapy approach employs a two-pronged attack against solid tumors to boost the immune system's ability to target and eliminate cancer cells. By combining CV1-producing T cells with cancer-targeting antibodies, researchers improved macrophage consumption of tumor cells, suggesting a potential solution to treatment challenges.